Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totaling 12,126 shares, a growth of 73.3% from the April 30th total of 6,999 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 23,966 shares, the short-interest ratio is presently 0.5 days.

Bolt Biotherapeutics Stock Down 4.1%

Shares of Bolt Biotherapeutics stock traded down $0.21 during midday trading on Wednesday, hitting $4.90. The company had a trading volume of 3,482 shares, compared to its average volume of 25,920. Bolt Biotherapeutics has a 52-week low of $3.91 and a 52-week high of $7.35. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The stock has a market capitalization of $9.41 million, a P/E ratio of -0.30 and a beta of 1.12. The company has a 50 day moving average of $4.75 and a 200 day moving average of $5.09.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. On average, equities analysts predict that Bolt Biotherapeutics will post -11.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

BOLT has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Rodman & Renshaw initiated coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 target price for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $34.67.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several institutional investors have recently modified their holdings of BOLT. Renaissance Technologies LLC raised its position in Bolt Biotherapeutics by 40.3% in the 1st quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after buying an additional 22,200 shares during the last quarter. T3 Companies LLC purchased a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at approximately $208,000. Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics during the fourth quarter valued at approximately $112,000. Susquehanna International Group LLP purchased a new stake in Bolt Biotherapeutics in the third quarter worth approximately $89,000. Finally, Shay Capital LLC bought a new stake in Bolt Biotherapeutics in the 3rd quarter worth approximately $85,000. 86.70% of the stock is owned by hedge funds and other institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.